A next-generation vaccine developed by Sanofi and GSK to be used as a booster has demonstrated good efficacy against variants of Covid including Omicron Sanofi today announced the results of two studies VAT Cohort and COVIBOOST VAT conducted on its new vaccine candidate booster adjuvant next generation GSK pandemic adjuvant containing Beta variant antigen In the Phase VAT Cohort study, the vaccine candidate induced a postimmunization day significant increase in antibody titres from baseline against multiple variants of interest fold increase against the parental virus D fold increase against Beta strain in adults previously immunized with mRNA technology COVID vaccines In particular against Omicron preliminary data showed fold increase against Omicron BA subvariant The vaccine generated double the number of neutralizing antibodies against Omicron BA and BA versus original Wuhan strain D-based booster